Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Nicot

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 12, 2021
Evaluation of two RT-PCR screening assays for identifying SARS-CoV-2 variantsM Migueres, S Lhomme, P Trémeaux, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple TherapyC Laouénan, J Guedj, G Peytavin, et al.
Journal of Medical Virology|January 26, 2011
Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapyF Nicot, L Alric, K Barange, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 12, 2021
Evaluation of two RT-PCR screening assays for identifying SARS-CoV-2 variantsM Migueres, S Lhomme, P Trémeaux, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple TherapyC Laouénan, J Guedj, G Peytavin, et al.
Journal of Medical Virology|January 26, 2011
Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapyF Nicot, L Alric, K Barange, et al.
Pageof 2